Drug Type Small molecule drug |
Synonyms Co-Dio, Co-Diovan, Co-Tareg + [26] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (06 Mar 1998), |
RegulationPriority Review (CN) |
Molecular FormulaC31H37ClN8O7S2 |
InChIKeyUIYUUEDFAMZISF-FTBISJDPSA-N |
CAS Registry186615-83-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | US | 06 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 3 | US | 01 Oct 2005 |
Phase 4 | 384 | (Valsartan) | rdknavcwuh(idgjhcwuta) = aeywgipwzh swesynncap (tdqiqwlfvy, ikoydjctni - gdflgoxnsp) View more | - | 15 Dec 2010 | ||
(HCTZ) | rdknavcwuh(idgjhcwuta) = yinuhuibhx swesynncap (tdqiqwlfvy, ujnrxgzrgp - cqcilcbnhe) View more | ||||||
Phase 4 | 412 | ylhwozaglu(nmqndfwqfl) = agknfxielj tztoujeqti (jlgsmdatpd, yvveveinwm - joyrnjknnn) View more | - | 10 Feb 2009 |